Jefferies Pharma Ratings: Underperform Calls on Dr Reddy’s and Cipla, Buy Call on Mankind Pharma

Jefferies pharma ratings released today present a mixed picture across three major Indian pharmaceutical stocks, with the brokerage remaining bearish on Dr Reddy’s Laboratories and Cipla while turning bullish on Mankind Pharma. The contrasting calls in these Jefferies pharma ratings come as DRL separately posted a sharp decline in today’s session on other company-specific factors.

Click Here – Get Free Investment Predictions

Jefferies Pharma Ratings: Summary Table

The table below lists the three Jefferies pharma ratings released today across the sector.

Stock	Rating	Target Price
Dr Reddy’s Laboratories	Underperform	Rs 1,040 per share
Cipla	Underperform	Rs 1,120 per share
Mankind Pharma	Buy	Rs 3,000 per share

Get Pharma Sector Brokerage Views from SEBI Registered Investment Advisors

Why These Jefferies Pharma Ratings Remain Bearish on DRL and Cipla

The common thread across these Jefferies pharma ratings’ underperform calls on both Dr Reddy’s Laboratories and Cipla is the brokerage’s view that these stocks offer limited upside even under favourable assumptions. For Dr Reddy’s, Jefferies’ note suggests the company’s growth drivers, whether from generics pipeline execution, biosimilars, or other segments, do not appear sufficient to justify a materially higher valuation than the current Rs 1,040 target implies, even in scenarios where the company executes well. Notably, Dr Reddy’s Laboratories has also been the sharpest faller among Nifty stocks in today’s broader market session, dropping between 5.58 and 6.38 percent depending on the reading, a decline that appears driven by separate company-specific developments rather than today’s Jefferies note itself.

For Cipla, Jefferies has been explicit that the stock’s bull case is contingent on timely US drug approvals coming through as expected. This framing highlights the binary, event-driven nature of pharmaceutical stock valuations tied to regulatory outcomes, where delays or rejections in the US FDA approval pipeline can materially alter a company’s growth trajectory and, by extension, brokerage price targets. This underperform stance in the Jefferies pharma ratings suggests the brokerage is not confident enough in the timing or certainty of these approvals to build them into a more bullish base case.

Why These Jefferies Pharma Ratings Have Turned Bullish on Mankind Pharma

In contrast, this Jefferies pharma ratings buy call on Mankind Pharma, with a Rs 3,000 target price, is built on the view that the stock’s downside now appears limited given early signs of business recovery. This suggests Mankind Pharma may have gone through a period of weaker performance or investor concern that is now showing signs of stabilising or reversing, giving Jefferies confidence to recommend the stock with a favourable risk-reward skew in these pharma ratings even without necessarily projecting explosive growth from current levels.

What These Jefferies Pharma Ratings Mean for Sector Investors

Today’s Jefferies pharma ratings illustrate how differentiated brokerage views can be even within the same sector, with company-specific factors such as US regulatory pipeline strength, domestic market recovery signals, and valuation starting points driving meaningfully different conclusions across these Jefferies pharma ratings for DRL, Cipla, and Mankind Pharma. Investors should note that these are single-brokerage calls and should be weighed alongside other analyst views and each company’s own quarterly results and management commentary, rather than treated as definitive verdicts on any of the three stocks.

What Investors Should Watch Next After These Jefferies Pharma Ratings

For Dr Reddy’s Laboratories and Cipla, investors should watch for updates on US FDA approval timelines and pipeline execution that could shift Jefferies’ underperform stance, along with each company’s upcoming quarterly results for signs of the growth drivers the brokerage currently views as insufficient. For Mankind Pharma, confirmation of the early recovery signs Jefferies has flagged, through sustained volume growth or margin improvement in subsequent quarters, will be the key test of whether the bullish call proves well timed.

How to Read Divergent Brokerage Calls Within a Sector

It is worth noting that these Jefferies pharma ratings today do not exist in isolation, and investors following these three stocks should be aware that other brokerages may hold materially different views based on their own models and assumptions. Divergent ratings within the same sector are common in pharmaceutical investing precisely because company-specific factors, such as a particular drug’s regulatory pathway, patent cliff exposure, or domestic versus export revenue mix, can vary substantially even among companies that appear similar on the surface. Rather than treating any single brokerage’s calls as the final word on these Jefferies pharma ratings, investors are better served by cross-referencing multiple analyst views alongside their own assessment of each company’s pipeline strength, balance sheet, and recent execution track record.

The pharmaceutical sector as a whole continues to navigate a mix of opportunities and risks, including US pricing pressure, the pace of new drug approvals, and domestic market growth trends, all of which feed into how brokerages like Jefferies calibrate their pharma ratings and target prices across individual names within the space.

Download the Univest iOS App or Univest Android App to track pharma sector brokerage ratings and stock updates live.

Conclusion

These Jefferies pharma ratings draw a clear line between Dr Reddy’s Laboratories and Cipla, where the brokerage sees limited upside even in bull cases, and Mankind Pharma, where early recovery signs support a buy call with a Rs 3,000 target. Investors across all three stocks should track the specific catalysts flagged in these Jefferies pharma ratings, from US approvals to recovery signals, to gauge how these calls play out in the coming quarters.

Frequently Asked Questions FAQs

What is Jefferies’ rating on Dr Reddy’s Laboratories?

Ans. Jefferies has an underperform call on Dr Reddy’s Laboratories with a target price of Rs 1,040 per share, arguing the stock offers limited upside even in bull-case scenarios.

What is Jefferies’ rating on Cipla?

Ans. Jefferies also has an underperform call on Cipla with a target price of Rs 1,120 per share, noting that the stock’s bull case depends heavily on timely US drug approvals materialising as expected.

What is Jefferies’ rating on Mankind Pharma?

Ans. Jefferies has a buy call on Mankind Pharma with a target price of Rs 3,000 per share, citing that the stock’s downside appears limited amid early signs of business recovery.

Why does Jefferies see limited upside for DRL and Cipla even in bull cases?

Ans. Jefferies’ underperform calls on both Dr Reddy’s Laboratories and Cipla suggest the brokerage believes even favourable scenarios, such as successful new product launches or regulatory approvals, would not be enough to justify significantly higher valuations for these two stocks relative to their current levels and Jefferies’ target prices.

Why is Cipla’s bull case tied to US drug approvals specifically?

Ans. Cipla has meaningful exposure to the US generics and specialty pharmaceutical market, so the timing and success of pending drug approvals from the US FDA are a key swing factor for the company’s revenue growth, and Jefferies flags that without these approvals materialising on schedule, the stock’s upside case weakens considerably.

What does ‘early recovery signs’ mean for Jefferies’ bullish Mankind Pharma call?

Ans. Jefferies’ reference to early recovery signs suggests the brokerage has observed initial positive indicators in Mankind Pharma’s business performance or demand trends that support its view the stock’s downside risk is now limited, underpinning the buy rating and Rs 3,000 target price.